ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1829

Ability of Inflammatory and Regulatory Soluble Mediators to Forecast Impending Clinical Disease Flare and Inform a Refined Lupus Flare Prediction Index in a Confirmatory Cohort of SLE Patients

Melissa E. Munroe1, Sarah Kleckner 1, Wade DeJager 1, Susan R. Macwana 1, Joel Guthridge 2, Eldon Jupe 3, Mohan Purushothaman 3, Sanjiv Sharma 3, Nancy Redinger 1, Teresa Aberle 1, Stan Kamp 1, Cristina Arriens 2, Eliza F. Chakravarty 2, Joan T. Merrill 4 and Judith James 2, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Progentec Diagnostics, Inc., Oklahoma City, OK, 4Okalahoma Medical Research Foundation, Oklahoma City, OK

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: cytokines and chemokines, Diagnostic Tests, Disease Activity, SLE

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: 3S082: SLE – Clinical II: Flares & Morbidity of SLE (1824–1829)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: SLE is marked by altered immune regulation linked to waxing and waning clinical disease activity. This study seeks to verify the alteration of inflammatory and regulatory mediators prior to clinical disease flare in a confirmatory cohort of SLE patients, seeking the best mediators to inform our Lupus Flare Prediction Index (LFPI).

Methods: Immune mediators were evaluated by xMAP assay in pre-flare (n=90) and “self” pre-nonflare (SNF) plasma samples (n=90) from the same female patients (49 European-, 41 African-American) with classified SLE (≥4 ACR criteria), as well as 48 race/age matched healthy controls (HC). Hybrid SLEDAI (hSLEDAI) scores, clinical features, medication usage, and the presence of SLE-associated autoantibody (AutoAb) specificities, including dsDNA, chromatin, Ro/SSA, La/SSB, Sm, SmRNP, and RNP, were also compared at pre-flare (100 ± 40 days prior to flare) vs. pre-SNF (96 ± 40 days prior to SNF) time points. A subset of 31, log-transformed, immune mediators were further evaluated using applied machine learning modeling approaches (random forest and XG Boost) to determine an optimal subset of mediators to inform the LFPI. The LFPI is the sum of log-transformed, standardized immune mediators, weighted by the Spearman r correlation coefficient of pre-flare/SNF immune mediator levels vs. hSLEDAI scores at disease flare/SNF.

Results: We did not observe differences with respect to hSLEDAI scores, clinical features, medication usage, or number and type of SLE-associated AutoAbs comparing pre-flare vs. pre-SNF time points, either in aggregate or by race. At follow-up, SLE patients experiencing a clinical disease flare (vs. SNF visit) had significantly elevated hSLEDAI scores (p< 0.0001), with an increased presence of arthritis (p< 0.0001), mucocutaneous (p< 0.0001), and serositis (p=0.0066) clinical features. Thirty-one immune mediators (Figure [A]) were altered in cases vs HC (p≤0.05), and altered in pre-flare vs. pre-SNF samples (p≤0.02 after adjusting for multiple comparison); inflammatory mediators were increased and regulatory mediators decreased in pre-flare samples. Variable importance of the 31 mediators was determined by random forest (Figure [A]) and confirmed by XG Boost. Forward selection/backward elimination drew 9-14 mediators that best differentiated pre-flare from pre-SNF (Table). A combination of the top 10 immune mediators best informed and maximized the performance of a newly refined LFPI (Figure [B]), achieving 87% sensitivity and 91% specificity. In addition to identifying impending clinical disease flare, the LFPI (and top mediators informing it) was significantly increased in SLE patients who went on to increased features of arthritis (p< 0.0001), mucocutaneous (p< 0.0001), or serositis (p=0.0003) clinical features at follow-up.

Conclusion: We verified the alteration of inflammatory and regulatory immune mediators with imminent lupus disease flare. A subset of mediators boosted the LFPI to identify SLE patients at risk of imminent flare who would benefit from early intervention strategies. Such an approach would be a game changer in prospective clinical trials and the management of lupus.

Determination of the top soluble mediators -A- to inform the Lupus Flare Prediction Index -LFPI- and its ability to differentiate SLE patients with imminent clinical disease flare -Pre-Flare- from the same patients during a comparable “self” non-flare -Pre-SNF- period of clinical disease activity -B-.


Disclosure: M. Munroe, Progentec Diagnostics, Inc., 2; S. Kleckner, None; W. DeJager, None; S. Macwana, None; J. Guthridge, DxTerity, 2; E. Jupe, Progentec Diagnostics, Inc., 3; M. Purushothaman, Progentec Diagnostics, Inc., 3; S. Sharma, Progentec Diagnostics, Inc., 3; N. Redinger, None; T. Aberle, None; S. Kamp, None; C. Arriens, AstraZeneca, 5, BMS, 2, 5, Exagen, 2, GSK, 2, 5; E. Chakravarty, None; J. Merrill, Abbvie, 5, Amgen, 5, Astellas, 5, AstraZeneca, 5, BMS, 2, 5, Celgene, 5, EMD Serono, 5, GSK, 2, 5, Idorsia, 5, ILTOO, 5, Immupharma, 5, Incyte, 5, Janssen, 5, Lilly, 5, Remegen, 5, Servier, 5, Xencor, Inc., 2; J. James, Abbvie, 5, Janssen, 5, Progentec, 2, Progentec Diagnostics, Inc., 2, Xencor, 2, Xencor, Inc., 2.

To cite this abstract in AMA style:

Munroe M, Kleckner S, DeJager W, Macwana S, Guthridge J, Jupe E, Purushothaman M, Sharma S, Redinger N, Aberle T, Kamp S, Arriens C, Chakravarty E, Merrill J, James J. Ability of Inflammatory and Regulatory Soluble Mediators to Forecast Impending Clinical Disease Flare and Inform a Refined Lupus Flare Prediction Index in a Confirmatory Cohort of SLE Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/ability-of-inflammatory-and-regulatory-soluble-mediators-to-forecast-impending-clinical-disease-flare-and-inform-a-refined-lupus-flare-prediction-index-in-a-confirmatory-cohort-of-sle-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ability-of-inflammatory-and-regulatory-soluble-mediators-to-forecast-impending-clinical-disease-flare-and-inform-a-refined-lupus-flare-prediction-index-in-a-confirmatory-cohort-of-sle-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology